Get Started on VPRIV
In order to begin treatment with VPRIV, you should work with your physician to complete, sign and submit a Start Form, available for download.
If you have questions about the form, please contact us
OnePath® Services
Learn about the many support services that OnePath® can offer you
OnePath® is a comprehensive and personalized support program for eligible patients, families, and healthcare providers needing assistance with approved Shire Human Genetic Therapies, Inc. products.
LEARN MOREBrochures
Helpful materials to benefit you.
Shire Human Genetic Therapies, Inc. offers many materials providing information on treating type 1 Gaucher disease with VPRIV and product support assistance through OnePath®.
LEARN MOREPatient Resources
The following websites provide additional information about type 1 Gaucher disease, and, in some cases, give you the opportunity to connect with others:
Children’s Gaucher Research Fund (www.childrensgaucher.org)
A nonprofit organization devoted to raising funds for research in types 2 and 3 Gaucher disease and providing support to families affected by Gaucher. Includes a section on actual family stories.
Gaucher Patients (www.gaucherpatients.com)
A Shire Human Genetic Therapies, Inc.-sponsored site where you can learn the basics of type 1 Gaucher disease, read Gaucher-related news, and network with a community of people with Gaucher disease.
Jewish Genetic Disease Consortium (www.jewishgeneticdiseases.org)
A group of organizations dedicated to strengthening awareness about genetic diseases through research and education. Also provides care for those directly affected by a rare disease.
National Gaucher Foundation (www.gaucherdisease.org)
Provides information on research, financial assistance, education and awareness, legislative issues, outreach programs, as well as live web-based meetings, national conferences, and patient meetings.
National Organization for Rare Disorders (NORD) (www.rarediseases.org)
Contains information about diseases, referrals to patient organizations, research grants and fellowships, advocacy and medication assistance programs, and networked peer-to-peer support for Gaucher.
National Society of Genetic Counselors (www.nsgc.org)
Provides assistance in helping people find genetic counseling in their area.
OnePath.com (www.OnePath.com)
A Shire Human Genetic Therapies, Inc.-sponsored site offering comprehensive, personalized product services and support for eligible patients who have rare diseases, as well as for their families and healthcare providers.
Rareshare (www.rareshare.org)
A unique social hub that helps build communities for patients and families affected by rare disorders, including Gaucher disease, and their healthcare professionals.
Yahoo Groups: Gaucher (http://health.groups.yahoo.com/group/gaucherdisease/)
Group websites where patients can chat online with fellow patients about issues with Gaucher disease. Additional resources and organizations are also listed: Search: 'Yahoo Gaucher Listserv'.
Shire Human Genetic Therapies, Inc. does not maintain or control the content on the websites listed here, with the exception of gaucherpatients.com and OnePath.com.
For more information about Type 1 Gaucher disease, go to gaucherpatients.com.
VPRIV is available by prescription only.
Indication
VPRIV is a hydrolytic lysosomal glucocerebroside-specific enzyme indicated for long-term enzyme replacement therapy (ERT) for pediatric and adult patients with type 1 Gaucher disease.
Important Safety Information
- The most serious side effects seen in patients in clinical trials with VPRIV were allergic reactions. Patients who have experienced allergic reactions to VPRIV or to other enzyme replacement therapy should proceed with caution.
- The most common side effects observed in clinical trials in patients treated with VPRIV were infusion-related and included: headache, dizziness, low blood pressure, high blood pressure, nausea, weakness/fatigue, and fever. Generally, infusion-related reactions were mild and, in newly treated patients, occurred mostly during the first 6 months of treatment and tended to occur less frequently with time.
- Management of infusion-related reactions is based on severity and may include slowing the infusion rate, treatment with medications such as antihistamines, fever-reducing agents and/or corticosteroids, and/or stopping and resuming treatment with increased infusion time. Side effects and any treatment concerns should be discussed with your physician.
- The most commonly reported side effects (occurring in ≥10% of patients) that were considered related to VPRIV included: headache, dizziness, abdominal pain, nausea, back pain, joint pain, upper respiratory tract infection, aPTT prolonged (eg, blood clotting difficulty), infusion-related reactions, fever, and weakness/fatigue.
- All adult side effects of VPRIV are considered relevant to children (ages 4 to 17 years). Side effects more commonly seen in children compared with adult patients included: upper respiratory tract infection, rash, aPTT prolonged, and fever. The safety of VPRIV has not been established in patients younger than 4 years of age.
- As with all therapeutic proteins, there is the potential of developing antibodies. It is unknown if the presence of antibodies to VPRIV is associated with a higher risk of infusion reactions. Patients with an immune response to other enzyme replacement therapies who are switching to VPRIV should continue to be monitored for antibodies.
- Your doctor may prescribe VPRIV to you if you are pregnant, only if it is clearly necessary.
- Tell your healthcare provider if you experience any side effects. For more information about VPRIV, ask your healthcare provider, read the Full Prescribing Information, visit www.VPRIV.com, or call Shire at 1-866-888-0660.
- You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.
